Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:492633rdf:typepubmed:Citationlld:pubmed
pubmed-article:492633lifeskim:mentionsumls-concept:C0919267lld:lifeskim
pubmed-article:492633lifeskim:mentionsumls-concept:C0020437lld:lifeskim
pubmed-article:492633lifeskim:mentionsumls-concept:C1441055lld:lifeskim
pubmed-article:492633pubmed:issue4lld:pubmed
pubmed-article:492633pubmed:dateCreated1979-12-27lld:pubmed
pubmed-article:492633pubmed:abstractTextTwo cases of paraneoplastic hypercalcemia secondary to ovarian tumors are presented. Both cases were secondary to ectopic parathormone (PTH) production. Other mediators postulated to cause this syndrome are prostaglandins, vitamin D-like sterols, non-vitamin D sterols, vitamin A, cortisol, and "osteoclast-activating factor.' The key treatment modalities for acute hypercalcemia are hydration and diuresis with furosemide; phosphates, steroids, antiprostaglandins, and hemodialysis may also be of value. Calcitonin is theoretically the most attractive treatment modality, but the rapid development of resistance limits its use to acute management. Mithramycin is most effective for long-term palliation of hypercalcemia if tumor-directed therapy is unsuccessful. Review of the literature confirms the previously made observation that mesonephromas are disproportionaately represented in association with this syndrome.lld:pubmed
pubmed-article:492633pubmed:languageenglld:pubmed
pubmed-article:492633pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:492633pubmed:citationSubsetAIMlld:pubmed
pubmed-article:492633pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:492633pubmed:statusMEDLINElld:pubmed
pubmed-article:492633pubmed:monthOctlld:pubmed
pubmed-article:492633pubmed:issn0029-7844lld:pubmed
pubmed-article:492633pubmed:authorpubmed-author:JohnsonT...lld:pubmed
pubmed-article:492633pubmed:authorpubmed-author:HoltzGGlld:pubmed
pubmed-article:492633pubmed:authorpubmed-author:SchrockM EMElld:pubmed
pubmed-article:492633pubmed:issnTypePrintlld:pubmed
pubmed-article:492633pubmed:volume54lld:pubmed
pubmed-article:492633pubmed:ownerNLMlld:pubmed
pubmed-article:492633pubmed:authorsCompleteYlld:pubmed
pubmed-article:492633pubmed:pagination483-7lld:pubmed
pubmed-article:492633pubmed:dateRevised2009-10-26lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-H...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-A...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-S...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-P...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-O...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-F...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-A...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-H...lld:pubmed
pubmed-article:492633pubmed:meshHeadingpubmed-meshheading:492633-P...lld:pubmed
pubmed-article:492633pubmed:year1979lld:pubmed
pubmed-article:492633pubmed:articleTitleParaneoplastic hypercalcemia in ovarian tumors.lld:pubmed
pubmed-article:492633pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:492633pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:492633lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:492633lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:492633lld:pubmed